Health

Pharmaceutical Deals and Withdrawals

Updated 2026-09-29 13:40 UTC 1 source Neutral

Novo Nordisk has licensed an experimental weight loss pill from Hengrui Pharma for $2.6 billion, while Merck is withdrawing its antibiotic. These moves reflect ongoing changes in the pharmaceutical industry.

Coverage timeline — 1 article

STAT News

STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma

2026-09-29 13:25 UTC